Research & Development
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
The lack of a genetic driver of metastatic cancer has led researchers to look for other causes of disease progression.
March 23, 2023
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
The researchers identified a set of biomarkers that may help distinguish whether pancreatic cysts are likely to develop into cancer or remain benign.
March 17, 2023
BlueStar Genomics announces rebranding as ClearNote Health, commercialization of pancreatic cancer test
The DNA-based blood test is already available in the U.S. through the ClearNote Health physician experience program.
December 22, 2022
Biological Dynamics embarks on clinical utility studies for pancreatic cancer detection assay
Biological Dynamics said that it is collaborating with Qure Healthcare and Curta to also evaluate the effects of its pancreatic cancer detection assay on patient outcomes and healthcare economics.
November 23, 2022
University of Pittsburgh NGS test shows high sensitivity in pancreatic cyst study
By sequencing 22 pancreatic cyst-associated genes, the PancreaSeq test distinguished benign cysts from those that could become cancerous.
October 6, 2022
Immunovia nabs CMS preliminary payment determination
The CMS preliminary payment determination implied a test price of $897.
September 26, 2022
Immunovia nabs California approval for pancreatic cancer test
The California Department of Public Health has granted Immunovia a clinical and public health laboratory license for the test, Immunovia said Thursday.
August 10, 2022
Guardant highlights data on multicancer test at AACR 2022
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
AI spots patients at elevated risk for pancreatic cancer
A team of researchers from the U.S. and Denmark used electronic health record (EHR) data from the Danish National Patient Registry to train their algorithm and then tested it on electronic medical records from Mass General Brigham Health Care System in Boston. Their model proved to be highly accurate for predicting patients at high risk for pancreatic cancer on large datasets from both countries.
April 8, 2022
Immunovia touts performance of PanCan-d test in clinical study
The test detected pancreatic ductal adenocarcinoma with 99% specificity and 89% sensitivity in stage I/II when excluding individuals with low levels of CA 19-9, an antigen released by pancreatic cancer cells.
February 17, 2022
PerkinElmer introduces 4 new ready-to-use KRAS assay kits
Designed to help researchers better understand KRAS protein structures and mutations, the kits all come with recombinant proteins, detection reagents, and assay buffers, according to the company.
July 28, 2021
PanCan, GeneCentric partner on precision medicine for pancreatic cancer
The partnership is designed to improve treatment response and survival rates of patients with pancreatic ductal adenocarcinoma (PDAC) tumors. It will utilize PanCan's patient molecular and outcomes data and GeneCentric's RNA-based portfolio, which includes the PurlSt profiler that identifies PDAC subtypes.
July 30, 2020
Page 1 of 2